Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
Delayed Quote. Delayed Swiss Exchange - 09/13 11:31:24 am
86.66 CHF   -1.52%
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
09/13NOVARTIS : The Startup That Manipulated Data to Get a Miracle Drug to Market
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 12:53pm EDT

By Donato Paolo Mancini

Novartis AG's (NOVN.EB) closed higher on Thursday after jumping on news of a ruling that suggested that market exclusivity for the company's multiple-sclerosis blockbuster drug Gilenya in the U.S. will likely be extended.

"A favorable resolution of the dosage regimen patent litigation" may lengthen the period in which the drug is free from generic competition, according to a Novartis document seen by Dow Jones Newswires.

The note was sent out at around midday Thursday, two analysts told Dow Jones, and shares started climbing around that time. One of the analysts said the market wasn't expecting the decision, so that sent the share price up.

According to the document, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office issued a decision upholding the validity of the dosage-regimen patent on Wednesday. The decision can be appealed, the document said.

Gilenya had sales of $3.19 billion in 2017, according to the company's annual report.

Novartis said it was pleased with the decision, and that it expected to maintain exclusivity until August 2019.

Shares closed up 4.1% at CHF78.94.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
09/13NOVARTIS : The Startup That Manipulated Data to Get a Miracle Drug to Market
DJ
09/13NOVARTIS : The Startup That Manipulated Data to Get a -2-
DJ
09/13NOVARTIS : New Novartis data show Mayzent can help preserve mobility for longer ..
AQ
09/13NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
PU
09/12NOVARTIS : New Novartis data show Mayzent® can help preserve mobility for longer..
PU
09/11Swiss Biotech Anokion Raises $40 Million in Series B Round
DJ
09/10NOVARTIS : NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities ..
BU
09/10NOVARTIS : data confirm long-term efficacy and safety of Aimovig for majority of..
AQ
More news
Financials (USD)
Sales 2019 46 926 M
EBIT 2019 13 830 M
Net income 2019 10 117 M
Debt 2019 17 463 M
Yield 2019 3,39%
P/E ratio 2019 18,9x
P/E ratio 2020 20,6x
EV / Sales2019 4,64x
EV / Sales2020 4,28x
Capitalization 200 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,54  $
Last Close Price 87,47  $
Spread / Highest target 22,9%
Spread / Average Target 8,08%
Spread / Lowest Target -6,80%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS18.45%200 777
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVO NORDISK AS14.89%118 168